Drug Profile
CVMG 01
Alternative Names: CV-MG-01; MyasterixLatest Information Update: 11 Oct 2021
Price :
$50
*
At a glance
- Originator CuraVac
- Class Peptides; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Myasthenia gravis
Most Recent Events
- 11 Oct 2021 Discontinued - Phase-II/III for Myasthenia gravis in Belgium (SC)
- 11 Oct 2021 Discontinued - Phase-II/III for Myasthenia gravis in Netherlands (SC)
- 30 Sep 2018 CuraVAc completes a phase I trial in Myasthenia gravis in Belgium (SC) (NCT02609022)